SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-165696
Filing Date
2020-06-10
Accepted
2020-06-10 16:15:03
Documents
6
Period of Report
2020-06-09
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d857108d8k.htm 8-K 35153
2 EX-10.1 d857108dex101.htm EX-10.1 200268
3 EX-10.2 d857108dex102.htm EX-10.2 109987
4 EX-99.1 d857108dex991.htm EX-99.1 22246
5 EX-99.2 d857108dex992.htm EX-99.2 11534
6 GRAPHIC g857108g36x31.jpg GRAPHIC 2988
  Complete submission text file 0001193125-20-165696.txt   384676
Mailing Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Business Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 617-651-8851
Fulcrum Therapeutics, Inc. (Filer) CIK: 0001680581 (see all company filings)

IRS No.: 474839948 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38978 | Film No.: 20954846
SIC: 2834 Pharmaceutical Preparations